Telix Pharmaceuticals Faces Class Action Lawsuit for Securities Law Violations

Tuesday, Nov 11, 2025 5:37 pm ET1min read

Telix Pharmaceuticals Limited is being sued for violating securities laws by overstating its progress in developing and commercializing prostate cancer treatments and exaggerating the strength of its supply chain. Shareholders who purchased shares during the class period (February 21, 2025 to August 28, 2025) are encouraged to contact the DJS Law Group to discuss their rights. The deadline for joining the case is January 9, 2026.

Telix Pharmaceuticals Faces Class Action Lawsuit for Securities Law Violations

Comments



Add a public comment...
No comments

No comments yet